Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 11/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23040084 | 0.91 | PARP10 (0.55) | PARP10PARP15FFAR1PPARDTLR4 | |
| SCHEMBL19834472 | 0.82 | TLR4 (0.42) | ACACAACACBFFAR1TLR4TLR2 | |
| SCHEMBL19834363 | 0.81 | ACACA (0.55) | ACACAACACBPARP10PARP15TLR4 | |
| SCHEMBL1564068 | 0.78 | MAOB (0.56) | FFAR1FFAR4 | |
| SCHEMBL19834611 | 0.78 | ACACA (0.58) | ACACAACACBPARP10PARP15FFAR1 | |
| SCHEMBL19406007 | 0.77 | ACACA (0.49) | ACACAACACBPARP10PARP15TLR4 | |
| SCHEMBL19834574 | 0.76 | ACACA (0.56) | ACACAACACBPARP10PARP15FFAR1 | |
| SCHEMBL19849103 | 0.76 | ACACA (0.56) | ACACAACACBTLR4TLR2 | |
| SCHEMBL23709919 | 0.76 | LMNA (0.50) | — | |
| SCHEMBL25487908 | 0.74 | PARP10 (0.47) | PARP10PARP15TLR4TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885PARP10 1775/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885PARP10 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.